mRNA-1345 is an investigational vaccine for the prevention of RSV in adults aged 60 years or older
TORONTO – Moderna Biopharma Canada Corp. has announced the filing of a New Drug Submission (NDS) to Health Canada for mRNA-1345, its investigational vaccine candidate for the prevention of RSV in adults aged 60 years or older. This is the first mRNA vaccine candidate for RSV filed in Canada. RSV is a major cause of lower respiratory tract infections in older adults and can cause a significant burden to health systems through hospitalizations and emergency care admissions. Mortality is more
common among the elderly hospitalized for RSV compared to other adults.
“We’ve seen the impact that respiratory viruses like RSV can have on the health and wellbeing of Canadians. As we approach the height of respiratory virus season, we’re pleased to now have a second vaccine candidate from our mRNA platform seeking regulatory approval in Canada,” said Leslie Madden, Head of Regulatory Science, Moderna Canada. “Our mRNA platform is enabling us to tackle this pervasive public health burden with speed and clinical rigor and we look forward to supporting the
Health Canada review of this important submission.”
